Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 18/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14384312 | 1.00 | EGLN3 (0.46) | EGLN3TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL16090981 | 0.87 | TBXAS1 (0.47) | EGLN3TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL2452910 | 0.81 | EGLN3 (0.49) | EGLN3TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL501640 | 0.79 | TBXAS1 (0.54) | EGLN3TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL26032565 | 0.79 | ATM (0.37) | MEN1KMT2A | |
| SCHEMBL26033595 | 0.78 | TBXAS1 (0.48) | TBXAS1MEN1KMT2A | |
| SCHEMBL28221409 | 0.78 | TBXAS1 (0.61) | TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL27352255 | 0.77 | TBXAS1 (0.53) | TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL10072238 | 0.76 | TBXAS1 (0.59) | EGLN3TBXAS1MEN1LMNAKMT2A | |
| SCHEMBL8032821 | 0.76 | TBXAS1 (0.50) | EGLN3TBXAS1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989478-B2 | decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-02 | — | — | US | disclosed |
| US-7691883-B2 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | SHIRAKI HIROAKI | 2010-04-01 | — | — | US | disclosed |
| US-20090143368-A1 | Use of Cinnamoyl Compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | COL2A1, MMP7, COL14A1 | EGLN3 122/4885TBXAS1 1274/4885MEN1 2870/4885 |
| US-20070265228-A1 | Cinnamoyl compound and use of the same | NPC1, CES2, CYP51A1 | EGLN3 155/4885TBXAS1 2029/4885MEN1 876/4885 |
| US-20090143368-A1 | Use of Cinnamoyl Compound | COL2A1, COL1A1, SMAD2 | EGLN3 170/4885TBXAS1 2045/4885MEN1 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.